Gardasil Efficacy In Adolescent Females Supported By Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Vaccines & Related Biological Products Advisory Committee unanimously agrees Merck’s human papillomavirus vaccine is safe and effective for use in females ages nine to 26 years.
You may also be interested in...
Merck’s Gardasil HPV Vaccine Clears FDA
The vaccine, which is administered in a three-dose series, is available for ordering at $120 per dose, Merck says.
Merck’s Gardasil HPV Vaccine Clears FDA
The vaccine, which is administered in a three-dose series, is available for ordering at $120 per dose, Merck says.
Gardasil Efficacy In Patients Already Infected With HPV Will Be Addressed By Advisory Panel
Potential of strains not contained in Merck’s HPV vaccine to offset efficacy of Gardasil will also be discussed at the committee’s May 18 meeting.